Valuation: ProPhase Labs, Inc.

Market Cap 1.07M 936K 866K 797K 1.51M 102M 1.54M 10.33M 4.05M 50.13M 4.01M 3.92M 173M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 9.59M 8.42M 7.79M 7.17M 13.56M 918M 13.83M 92.9M 36.43M 451M 36.03M 35.24M 1.56B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
91.93%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day+1.26%
1 week+4.90%
Current month-16.20%
1 month-9.29%
3 months-39.58%
6 months-61.41%
Current year-82.77%
1 week 0.07
Extreme 0.07
0.09
1 month 0.07
Extreme 0.07
0.12
Current year 0.07
Extreme 0.068
0.47
1 year 0.07
Extreme 0.068
6.66
3 years 0.07
Extreme 0.068
75.5
5 years 0.07
Extreme 0.068
152.5
10 years 0.07
Extreme 0.068
160.4
Manager TitleAgeSince
Chief Executive Officer 67 18/06/2009
Director of Finance/CFO 66 05/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 18/06/2009
Director/Board Member 70 31/05/2009
Director/Board Member 56 19/06/2025
Date Insider Type Main position Quantity % Market Cap.
08/09/25Free

Chief Executive Officer

500,000 1.2036%
16/02/25Free

Chief Operating Officer

500,000 1.6737%
13/02/25Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
+1.26%+4.90%-98.19%-99.89% 1.07M
-0.04%-4.76%+70.87%+432.15% 38.66B
+0.88%-1.74%+11.86%+31.97% 22.7B
-1.46%-1.51%-23.11%-39.58% 7.3B
-1.22%-5.86%+14.65%+112.10% 5.16B
+1.91%+4.82%+17.90%+44.90% 2.97B
-1.62%-5.78%-21.22%+833.96% 1.95B
-1.17%0.00%+33.47%-19.89% 1.84B
+0.64%-6.33%+97.77%-18.30% 1.84B
+5.58%+3.83%+26.36%+4.70% 1.75B
Average +0.44%-0.81%+13.04%+128.21% 8.42B
Weighted average by Cap. +0.12%-2.62%+38.20%+230.73%

Financials

2024 2025
Net sales 6.77M 5.94M 5.5M 5.06M 9.57M 648M 9.76M 65.55M 25.71M 318M 25.42M 24.87M 1.1B 4.34M 3.81M 3.53M 3.25M 6.14M 416M 6.26M 42.07M 16.5M 204M 16.32M 15.96M 705M
Net income -53.36M -46.81M -43.35M -39.89M -75.45M -5.11B -76.91M -517M -203M -2.51B -200M -196M -8.66B -14.74M -12.93M -11.98M -11.02M -20.84M -1.41B -21.25M -143M -55.99M -693M -55.36M -54.15M -2.39B
Net Debt 23.9M 20.96M 19.41M 17.86M 33.78M 2.29B 34.44M 231M 90.74M 1.12B 89.73M 87.77M 3.88B 8.53M 7.48M 6.93M 6.37M 12.06M 816M 12.29M 82.57M 32.38M 401M 32.02M 31.32M 1.38B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
13/07/26 US$0.0771 +1.26% 18,935
10/07/26 US$0.0761 0.00% 761
09/07/26 US$0.0761 +0.13% 4,863
08/07/26 US$0.0760 -15.37% 12,959
07/07/26 US$0.0898 +22.18% 2,260

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock